Cargando…

Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents

Ovarian cancer has the highest mortality rate among all gynecological malignancies; therefore, a novel treatment strategy is needed urgently. Utilizing immune checkpoint inhibitors has been considered for microsatellite instability (MSI)-high (MSI-H) tumors. However, the prevalence of MSI-H tumors i...

Descripción completa

Detalles Bibliográficos
Autores principales: Nonomura, Yuki, Nakayama, Kentaro, Nakamura, Kohei, Razia, Sultana, Yamashita, Hitomi, Ishibashi, Tomoka, Ishikawa, Masako, Sato, Seiya, Nakayama, Satoru, Otsuki, Yoshiro, Kyo, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032309/
https://www.ncbi.nlm.nih.gov/pubmed/35455871
http://dx.doi.org/10.3390/healthcare10040694
_version_ 1784692610952069120
author Nonomura, Yuki
Nakayama, Kentaro
Nakamura, Kohei
Razia, Sultana
Yamashita, Hitomi
Ishibashi, Tomoka
Ishikawa, Masako
Sato, Seiya
Nakayama, Satoru
Otsuki, Yoshiro
Kyo, Satoru
author_facet Nonomura, Yuki
Nakayama, Kentaro
Nakamura, Kohei
Razia, Sultana
Yamashita, Hitomi
Ishibashi, Tomoka
Ishikawa, Masako
Sato, Seiya
Nakayama, Satoru
Otsuki, Yoshiro
Kyo, Satoru
author_sort Nonomura, Yuki
collection PubMed
description Ovarian cancer has the highest mortality rate among all gynecological malignancies; therefore, a novel treatment strategy is needed urgently. Utilizing immune checkpoint inhibitors has been considered for microsatellite instability (MSI)-high (MSI-H) tumors. However, the prevalence of MSI-H tumors in ovarian endometrioid and clear cell carcinomas remains unclear. Here, polymerase chain reaction was used to analyze 91 cases of ovarian endometrioid and clear cell carcinomas for the MSI status and the relationship between MSI-H, immune checkpoint molecules, and clinicopathological factors (including patient survival). Only 5 of 91 (5%) cases were MSI-H endometrioid carcinomas. In these cases, CD-8 expression was significantly higher (p = 0.026), confirming an enhanced immune response. From the survival curve, no statistical correlations were found between the MSI-H group and the microsatellite stable (MSS) group; however, the MSS group trended towards better progression-free survival than the MSI-H group (p = 0.056). Patients with PD-L1 expression had shorter overall survival than those without (p = 0.022). Thus, MSI-H is a rare event and not a favorable prognostic factor in ovarian endometrioid and clear cell carcinomas. Thus, to improve the prognosis of ovarian endometrioid carcinoma and clear cell carcinomas, a combination therapy of immune checkpoint inhibitors and other molecular targeted therapies may be required.
format Online
Article
Text
id pubmed-9032309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90323092022-04-23 Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents Nonomura, Yuki Nakayama, Kentaro Nakamura, Kohei Razia, Sultana Yamashita, Hitomi Ishibashi, Tomoka Ishikawa, Masako Sato, Seiya Nakayama, Satoru Otsuki, Yoshiro Kyo, Satoru Healthcare (Basel) Article Ovarian cancer has the highest mortality rate among all gynecological malignancies; therefore, a novel treatment strategy is needed urgently. Utilizing immune checkpoint inhibitors has been considered for microsatellite instability (MSI)-high (MSI-H) tumors. However, the prevalence of MSI-H tumors in ovarian endometrioid and clear cell carcinomas remains unclear. Here, polymerase chain reaction was used to analyze 91 cases of ovarian endometrioid and clear cell carcinomas for the MSI status and the relationship between MSI-H, immune checkpoint molecules, and clinicopathological factors (including patient survival). Only 5 of 91 (5%) cases were MSI-H endometrioid carcinomas. In these cases, CD-8 expression was significantly higher (p = 0.026), confirming an enhanced immune response. From the survival curve, no statistical correlations were found between the MSI-H group and the microsatellite stable (MSS) group; however, the MSS group trended towards better progression-free survival than the MSI-H group (p = 0.056). Patients with PD-L1 expression had shorter overall survival than those without (p = 0.022). Thus, MSI-H is a rare event and not a favorable prognostic factor in ovarian endometrioid and clear cell carcinomas. Thus, to improve the prognosis of ovarian endometrioid carcinoma and clear cell carcinomas, a combination therapy of immune checkpoint inhibitors and other molecular targeted therapies may be required. MDPI 2022-04-07 /pmc/articles/PMC9032309/ /pubmed/35455871 http://dx.doi.org/10.3390/healthcare10040694 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nonomura, Yuki
Nakayama, Kentaro
Nakamura, Kohei
Razia, Sultana
Yamashita, Hitomi
Ishibashi, Tomoka
Ishikawa, Masako
Sato, Seiya
Nakayama, Satoru
Otsuki, Yoshiro
Kyo, Satoru
Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title_full Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title_fullStr Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title_full_unstemmed Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title_short Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
title_sort ovarian endometrioid and clear cell carcinomas with low prevalence of microsatellite instability: a unique subset of ovarian carcinomas could benefit from combination therapy with immune checkpoint inhibitors and other anticancer agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032309/
https://www.ncbi.nlm.nih.gov/pubmed/35455871
http://dx.doi.org/10.3390/healthcare10040694
work_keys_str_mv AT nonomurayuki ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT nakayamakentaro ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT nakamurakohei ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT raziasultana ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT yamashitahitomi ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT ishibashitomoka ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT ishikawamasako ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT satoseiya ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT nakayamasatoru ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT otsukiyoshiro ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents
AT kyosatoru ovarianendometrioidandclearcellcarcinomaswithlowprevalenceofmicrosatelliteinstabilityauniquesubsetofovariancarcinomascouldbenefitfromcombinationtherapywithimmunecheckpointinhibitorsandotheranticanceragents